

PERSONAL INFORMATION

Name **ELEONORA PALLUZZI**
Address **VIA VENEZIA 22B, FIANO ROMANO (RM), ITALIA**
Phone **3393312291**

E-mail **eleonora.palluzzi@policlinicogemelli.it**
C.F.: **PLLLNR83M57L182W**
Nationality **Italian**
Date of birth **17/08/1983**

WORK AND PROFESSIONAL EXPERIENCES

- Registered at the Order of Surgeons and Dentists of Rieti since 23/03/2009
- From 15/10/2014 to 2016 Fellow oncologist at the Day Hospital Tumori Femminili, Policlinico Agostino Gemelli, Rome
- From 2016 to May 2017 Freelance Oncologist at the Day Hospital dei Tumori Femminili of Fondazione Policlinico Agostino Gemelli, Rome
- From May 2017 Medical Oncologist at Day Hospital of Tumori Femminili of Fondazione Policlinico Agostino Gemelli, Rome

EDUCATION AND TRAINING

Qualifications:

Scientific High School Diploma achieved with a score of 100/100; 2002-2003

Degree in Medicine and Surgery at the University of Studies of L'Aquila on 25/07/2009 with a score of 110/110 with honors and commendation and discussion of the thesis "Standardization of schemes of chemotherapy in the treatment of breast cancer in elderly patients and / or with comorbidities - Supervisor: Prof. Enrico Ricevuto

Specialization in Medical Oncology achieved in July 2014 at the University of Studies of L'Aquila with a score of 50/50 and discussion of the thesis "Clinical outcome in metastatic renal cell carcinoma patients treated with sequential biological drugs: the experience on Medical Oncology, Supervisor: Chiar.mo Prof. E. Ricevuto

PERSONAL SKILLS AND COMPETENCES

NATIVE LANGUAGE

ITALIAN

OTHERS LANGUAGES

ENGLISH

- *READING ABILITY*
- *WRITING SKILLS*
- *ORAL EXPRESSION SKILLS*

Good

Good

Good

OTHER INFORMATIONS

Member of the Multicenter Italian Trials in ovarian cancer and gynecologic malignancies (MITO) since 2012

GCP certification since February 2016

ALS 2017 certification

ATTACHMENTS

Author of various scientific works:

Poster presenter at "18th International Meeting of the European Society of Gynaecological Oncology (ESGO): *"Efficacy of carboplatin /paclitaxel schedules tailored according to age and comorbidities in advanced ovarian cancer"*

Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer. Tudini M, **Palluzzi E**, Cannita K, Mancini M, Santomaggio A, Bruera G, Baldi PL, Pelliccione M, Ricevuto E, Ficorella C. *Oncol Rep.* 2012 Feb;27(2):423-32. doi: 10.3892/or.2011.1517. Epub 2011 Oct 21.

Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer. Irelli A, Bruera G, Cannita K, **Palluzzi E**, Gravina GL, Festuccia C, Ficorella C, Ricevuto E. *Biomed Res Int.* 2014;2014:909623. doi: 10.1155/2014/909623. Epub 2014 May 28. Review

Endometriosis-associated clear cell carcinoma arising in caesarean section scar: a case report and review of the literature. Ferrandina G, **Palluzzi E**, Fanfani F, Gentileschi S, Valentini AL, Mattoli MV, Pennacchia I, Scambia G, Zannoni G. *World J Surg Oncol.* 2016 Dec 3;14(1):300. Review.

Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey. Ferrandina G, Amadio G, Paris I, Distefano M, **Palluzzi E**, de Vincenzo R, Ricci C, Scambia G. *Int J Gynecol Cancer.* 2017 Jul;27(6):1141-1148.

Early detection of recurrence or progression disease in patients with ovarian cancer after primary debulking surgery. Correlation between CT findings and CA 125 levels. Giuliani M, Gui B, Valentini AL, DI Giovanni SE, Miccò M, Rodolfo E, Falcione M, DE Waure C, **Palluzzi E**, Salutati V, Scambia G, Manfredi R. *Minerva Ginecol.* 2017 Dec;69(6):538-547. doi: 10.23736/S0026-4784.17.04062-X. Epub 2017 Jun 9.

Optimizing treatment in recurrent epithelial ovarian cancer. Corrado G, Salutati V, **Palluzzi E**, Distefano MG, Scambia G, Ferrandina G. *Expert Rev Anticancer Ther.* 2017 Dec;17(12):1147-1158. doi: 10.1080/14737140.2017.1398088. Epub 2017 Nov 6. Review.

Author in the volume: *"Targeted Therapies for Solid Tumors: A handbook for Moving Toward New Frontiers in Cancer Treatments"* di capitolo dal titolo *"Role of Poly-ADP Ribose Polymerase (PARP) Inhibitors in triple negative breast cancer (TNBC)"*

Management of BRCA mutation carriers. Ida Paris, Danilo Di Giorgio, **Eleonora Palluzzi**, Giorgia Garganese, Daniela Andreina Terribile, Simona Maria Fragomeni, Sabatino D'Archi, Giovanni Scambia, Riccardo Masetti. Vol 7, Supplement 3 (April 2018): *Translational Cancer Research*

Neo-adjuvant platinum-based chemotherapy followed by chemoradiation

and radical surgery in locally advanced cervical cancer (Lacc) patients: A phase II study. Ferrandina G, **Palluzzi E**, Gallotta V, Gambacorta MA, Autorino R, Turco LC, Macchia G, Cosentino F, Gui B, Mattoli MV, Ronzino G, Valentini V, Scambia G. *Eur J Surg Oncol.* 2018 Jul;44(7):1062-1068. doi: 10.1016/j.ejso.2018.04.019. Epub 2018 May 3.

Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study. Marchetti C, Rosati A, Scaletta G, Pietragalla A, Arcieri M, Ergasti R, **Palluzzi E**, Scambia G, Fagotti A. *Gynecol Oncol.* 2019 Dec;155(3):400-405. doi: 10.1016/j.ygyno.2019.09.020. Epub 2019 Oct 9.

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer. Colombo N, Zaccarelli E, Baldoni A, Frezzini S, Scambia G, **Palluzzi E**, Tognon G, Lissoni AA, Rubino D, Ferrero A, Farina G, Negri E, Pesenti Gritti A, Galli F, Biagioli E, Rulli E, Poli D, Gerardi C, Torri V, Fossati R, D'Incalci M. *Br J Cancer.* 2019 Oct;121(9):744-750. doi: 10.1038/s41416-019-0584-5. Epub 2019 Sep 20.

New medical approaches in advanced ovarian cancer. Corrado G, **Palluzzi E**, Bottoni C, Pietragalla A, Salutari V, Ghizzoni V, Distefano M, Scambia G, Ferrandina G. *Minerva Med.* 2019 Aug;110(4):367-384. doi: 10.23736/S0026-4806.19.06139-1. Epub 2019 May 22. Review.

Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes. Nero C, Fagotti A, Zannoni GF, **Palluzzi E**, Scambia G, Petrillo M. *Int J Gynecol Cancer.* 2019 Jul;29(6):1064-1071. doi: 10.1136/ijgc-2019-000232. Epub 2019 May 5.

First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. Parisi A, **Palluzzi E**, Cortellini A, Sidoni T, Cocciolone V, Lanfiuti Baldi P, Porzio G, Ficarella C, Cannita K. *Clin Transl Oncol.* 2020 Jan;22(1):158-162. doi: 10.1007/s12094-019-02122-x. Epub 2019 Apr 30.

Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study. Ferrandina G, Corrado G, Vitrano G, Gallotta V, **Palluzzi E**, Distefano M, Scambia G. *Cancer Chemother Pharmacol.* 2019 Mar;83(3):431-438. doi: 10.1007/s00280-018-3742-1. Epub 2018 Dec 1.

Medical treatment of gynecologic cancer patients during COVID-19 pandemic. Palluzzi E, Corrado G, Bolomini G, Vertechy L, Bottoni C, Marchetti C, Distefano MG, Scambia G, Ferrandina G. *Accepted for publication at Int J Gyn Oncol, Feb 2021.*

Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis. Marchetti C, Rosati A, De Felice F, Boccia SM, Vertechy L,

Pavone M, **Palluzzi E**, Scambia G, Fagotti A. *Gynecol Oncol.* 2021 Jul 23:S0090-8258(21)00587-4.

Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance. E. Palluzzi, C. Marchetti, S Cappuccio, G. Avesani, G. Macchia, MG Gambacorta, F. Cocciolillo, G. Scambia, A. Fagotti. Int J Gynecol Cancer 2022;32:1164-1170

Data 3/11/2022

Signature

Dott.ssa E. Palluzzi